<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02506816</url>
  </required_header>
  <id_info>
    <org_study_id>MedOPP044</org_study_id>
    <nct_id>NCT02506816</nct_id>
  </id_info>
  <brief_title>Preoperative Olaparib Endometrial Carcinoma Study (POLEN)</brief_title>
  <acronym>Polen</acronym>
  <official_title>A Preoperative &quot;Window-opportunity&quot;, Multicenter, Pharmacokinetic-pharmacodynamic Study to Evaluate the Inhibitory Effects of Single Agent AZD2281 (Olaparib), in Patients With Early-stage Endometrial Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedSIR</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Experior</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>MedSIR</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to identify, in human tumour samples, biomarker
      changes associated to short exposure to AZD2281 as potential predictors of activity in
      Endometrial Carcinoma (EC).

      This is an exploratory study with a biological primary endpoint. Clinical efficacy or safety
      are not a primary objective of the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of the present proposal study is to assess the biological consequences of
      PARP inhibition in type I primary EC, in patients who receive therapy with AZD2281 during the
      period of time between diagnosis and surgery.

      This is a phase 0 trial or &quot;Exploratory Investigational New Drug&quot; study, a type of trial that
      involves limited number of patient under drug therapy and has no therapeutic or diagnostic
      intent because the drug exposure has a limited duration and the dosage is lower than 100% of
      the dose required to yield a pharmacologic effect.

      The purpose of the phase 0 studies is to assist in the go versus no-go decision-making
      process of a drug's fate earlier in the development process, using relevant human models
      instead of relying on sometimes inconsistent animal data, thus helping to confirm endpoints
      such as mechanism of action, pharmacology, bioavailability and pharmacodynamics.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">March 2019</completion_date>
  <primary_completion_date type="Actual">July 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Expression of Cell Cycle-related Proteins</measure>
    <time_frame>Baseline and Day 28 (+/- 5)</time_frame>
    <description>We assessed the change from baseline in the histological score (H-score) of the cell cycle-related proteins on endometrial tumor tissues after 28 (+/- 5) days of olaparib-based therapy. In detail, expression of the cyclin D1, Ki67, and caspase-3 active proteins evaluated by an H-score according to the following formula:
H-score= 1x(%light staining) + 2x(%moderate staining) + 3x(%strong staining).
The final score ranges from 0 to 300, where 0 indicates absence of staining (corresponding to the lowest tumor proliferation rate and better outcome) and 300 the maximum staining (corresponding to the highest tumor proliferation score and worse outcome).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Protein Expression of Biomarkers Related to PARP-inhibition</measure>
    <time_frame>Baseline and Day 28 (+/- 5)</time_frame>
    <description>We assessed the change from baseline in the H-score of several biomarkers targeted by olaparib-based therapy on endometrial tumor tissues after 28 (+/- 5) days of treatment. In detail, expression of protein involved in the DNA repair (PARP1, ɣH2AX), angiogenesis (VEG, HIF-1α, PTEN), apoptosis (p65, p50, p53), glucose metabolism (GLUT1), proliferation (PH3), and regulation of gene transcription (ARID1A) were evaluated by an H-score according to the following formula:
H-score= 1x(%light staining) + 2x(%moderate staining) + 3x(%strong staining).
The final score ranges from 0 to 300, where 0 indicates absence of staining and 300 the maximum staining.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Levels of Olaparib</measure>
    <time_frame>Days 7,14,21 and 28</time_frame>
    <description>Plasma concentration of olaparib administered at dosis of 300mg twice in a day (600mg/day). Values of plasma level of olaparib on days 7,14,21 and 28 were collected at time when maximum of drug concentration is reached. Data are reported as µg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Olaparib-Associated Toxicities</measure>
    <time_frame>Up to 28 days (+/- 5)</time_frame>
    <description>To assess the tolerability for all treated patients (N=36) according to NCI-CTCAE v.4.03.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">36</enrollment>
  <condition>Endometrial Carcinoma</condition>
  <arm_group>
    <arm_group_label>Olaparib</arm_group_label>
    <description>Drug exposure has a limited duration 28 (+/- 5) days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaparib</intervention_name>
    <description>Drug exposure has a limited duration 28 (+/- 5) days and at lower dose (600mg/day) than therapeutical accepted (800mg/day).</description>
    <arm_group_label>Olaparib</arm_group_label>
    <other_name>Lynparza</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tumor cells Plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patinets diagnosed with endometrial carcinoma prior surgery
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically-confirmed type I primary endometrial carcinoma (EC).
             Diagnosis biopsy must contain 3-12 mg of tumour cellularity/stroma (Tumour: 5-20 mm)
             and this will be checked in the central laboratory for this trial. If tumour
             cellularity/stroma is inadequate, one re-biopsy with adequate tumour
             cellularity/stroma will be mandatory before study entry.

          -  WHO performance status ≤ 2.

          -  Adequate bone marrow function as shown by: ANC ≥ 1.5 x 109/L, Platelets ≥ 100 x 109/L,
             Hb &gt;10g/dL.

          -  Adequate liver function as shown by:

        serum bilirubin ≤ 1.5 x ULN INR &lt; 1.3 (or &lt; 3 on anticoagulants) ALT and AST ≤ 2.5x ULN

          -  Adequate renal function: serum creatinine ≤ 1.5 x mg/dL.

          -  Fasting serum cholesterol ≤300 mg/dL or ≤7.75 mmol/L and fasting triglycerides ≤ 2.5 x
             ULN.

          -  Signed informed consent, including consent to tissue collection and blood samples as
             specified by the protocol.

        Exclusion Criteria:

          -  Subjects who have received prior anticancer therapies for the current endometrial
             cancer (including chemotherapy, radiotherapy, antibody based therapy, hormonotherapy
             or surgery).

          -  Patients, who have had a major surgery or significant traumatic injury within 4 weeks
             of start of study drug, patients who have not recovered from the side effects of any
             major surgery (defined as requiring general anesthesia) or patients that may require
             major surgery during the course of the study.

          -  Prior treatment with any investigational drug within the preceding 4 weeks.

          -  Patients receiving chronic, systemic treatment with corticosteroids or another
             immunosuppressive agent, except corticosteroids with a daily dosage equivalent to
             prednisone ≤ 20 mg. However, patients receiving corticosteroids must have been on a
             stable dosage regimen for a minimum of 4 weeks prior the study entry. Topical or
             inhaled corticosteroids are allowed.

          -  Patients who have received immunization with attenuated live vaccines within one week
             of study entry (note: during study period these kind of vaccines are also not
             allowed).

          -  Patients who have any severe and/or uncontrolled medical conditions or other
             conditions that could affect their participation in the study such as:

        Symptomatic congestive heart failure of New York heart Association Class III or IV Unstable
        angina pectoris, myocardial infarction within 6 months of start of study drug, Serious
        uncontrolled cardiac arrhythmia or any other clinically significant cardiac disease
        Severely impaired lung function Uncontrolled diabetes as defined by fasting serum glucose
        &gt;1.5 x ULN Active (acute or chronic) or uncontrolled severe infections Liver disease such
        as cirrhosis, chronic active hepatitis or chronic persistent hepatitis A known history of
        HIV seropositivity.

          -  Patients with an active, bleeding diathesis.

          -  Female patients who are pregnant or breast feeding, or adults of reproductive
             potential who are not using effective birth control methods. If barrier contraceptives
             are being used, these must be continued throughout the trial by both sexes. Hormonal
             contraceptives are acceptable as a sole method of contraception. (Women of
             childbearing potential must have a negative urine or serum pregnancy test within 7
             days prior to administration of AZD2281).

          -  History of noncompliance to medical regimens.

          -  Patients unwilling to or unable to comply with the protocol.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Llombart, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Medica SIR</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MedSIR investigative site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedSIR investigative site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedSIR investigative site</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedSIR investigative site</name>
      <address>
        <city>Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedSIR investigative site</name>
      <address>
        <city>Granollers</city>
        <zip>08400</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedSIR</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedSIR investigative site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedSIR investigative site</name>
      <address>
        <city>Santiago De Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedSIR investigative site</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedSIR investigative site</name>
      <address>
        <city>Vigo</city>
        <zip>36312</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>June 29, 2015</study_first_submitted>
  <study_first_submitted_qc>July 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2015</study_first_posted>
  <results_first_submitted>October 3, 2019</results_first_submitted>
  <results_first_submitted_qc>October 25, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 15, 2019</results_first_posted>
  <last_update_submitted>December 3, 2019</last_update_submitted>
  <last_update_submitted_qc>December 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olaparib</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 3, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/16/NCT02506816/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 11, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/16/NCT02506816/SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Out of 49 patients initially considered for study eligibility, 9 did not sign the ICF and 4 did not meet eligibility criteria (screen failures).
Out of 36 patients who were treated and included in the overall analysis and safety, 5 were excluded from the primary and secondary analysis because of no valid samples for biomarker characterization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Olaparib</title>
          <description>Drug exposure has a limited duration 28 (+/- 5) days.
Olaparib: Drug exposure has a limited duration 28 (+/- 5) days and at lower dose (600mg/day) than therapeutical accepted (800mg/day).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Samples Availability</title>
              <participants_list>
                <participants group_id="P1" count="31">31 of 36 patients had valid samples for analysis of biomarkers (primary and secondary analysis)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>A total of 36 patients were treated and included in the overall population and safety analyses.</population>
      <group_list>
        <group group_id="B1">
          <title>Olaparib</title>
          <description>Drug exposure has a limited duration 28 (+/- 5) days.
Olaparib: Drug exposure has a limited duration 28 (+/- 5) days and at lower dose (600mg/day) than therapeutical accepted (800mg/day).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>13 Screening Failures</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>13 Screening Failures</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <population>13 Screening Failures</population>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Expression of Cell Cycle-related Proteins</title>
        <description>We assessed the change from baseline in the histological score (H-score) of the cell cycle-related proteins on endometrial tumor tissues after 28 (+/- 5) days of olaparib-based therapy. In detail, expression of the cyclin D1, Ki67, and caspase-3 active proteins evaluated by an H-score according to the following formula:
H-score= 1x(%light staining) + 2x(%moderate staining) + 3x(%strong staining).
The final score ranges from 0 to 300, where 0 indicates absence of staining (corresponding to the lowest tumor proliferation rate and better outcome) and 300 the maximum staining (corresponding to the highest tumor proliferation score and worse outcome).</description>
        <time_frame>Baseline and Day 28 (+/- 5)</time_frame>
        <population>The analysis was performed in the complete population of analysis (N = 36) and in the population of biomarkers (N = 31).</population>
        <group_list>
          <group group_id="O1">
            <title>Olaparib</title>
            <description>Drug exposure has a limited duration 28 (+/- 5) days.
Olaparib: Drug exposure has a limited duration 28 (+/- 5) days and at lower dose (600mg/day) than therapeutical accepted (800mg/day).</description>
          </group>
        </group_list>
        <measure>
          <title>Expression of Cell Cycle-related Proteins</title>
          <description>We assessed the change from baseline in the histological score (H-score) of the cell cycle-related proteins on endometrial tumor tissues after 28 (+/- 5) days of olaparib-based therapy. In detail, expression of the cyclin D1, Ki67, and caspase-3 active proteins evaluated by an H-score according to the following formula:
H-score= 1x(%light staining) + 2x(%moderate staining) + 3x(%strong staining).
The final score ranges from 0 to 300, where 0 indicates absence of staining (corresponding to the lowest tumor proliferation rate and better outcome) and 300 the maximum staining (corresponding to the highest tumor proliferation score and worse outcome).</description>
          <population>The analysis was performed in the complete population of analysis (N = 36) and in the population of biomarkers (N = 31).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cyclin D1 pre-treatment - post-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.1" spread="62.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ki67 pre-treatment - post-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caspase-3 active pre-treatment - post-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>After having analyzed the H-score for each of 3 biomarkers, we calculated the change from baseline subtracting post-treatment H-score from baseline H-score. Data were expressed as mean value and relative standard deviation.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The P-valor Wilcoxon method is a non-parametric statistical hypothesis test used to evaluate changes from baseline H-score values of the three biomarkers.</non_inferiority_desc>
            <p_value>0.033</p_value>
            <p_value_desc>In order to adjust the multiple comparisons made, Benjamini–Hochberg’s false discovery rate (FDR) 10% method was used.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Protein Expression of Biomarkers Related to PARP-inhibition</title>
        <description>We assessed the change from baseline in the H-score of several biomarkers targeted by olaparib-based therapy on endometrial tumor tissues after 28 (+/- 5) days of treatment. In detail, expression of protein involved in the DNA repair (PARP1, ɣH2AX), angiogenesis (VEG, HIF-1α, PTEN), apoptosis (p65, p50, p53), glucose metabolism (GLUT1), proliferation (PH3), and regulation of gene transcription (ARID1A) were evaluated by an H-score according to the following formula:
H-score= 1x(%light staining) + 2x(%moderate staining) + 3x(%strong staining).
The final score ranges from 0 to 300, where 0 indicates absence of staining and 300 the maximum staining.</description>
        <time_frame>Baseline and Day 28 (+/- 5)</time_frame>
        <population>The analysis was performed in the complete population of analysis (N = 36) and in the population of biomarkers (N = 31).</population>
        <group_list>
          <group group_id="O1">
            <title>Olaparib</title>
            <description>Drug exposure has a limited duration 28 (+/- 5) days.
Olaparib: Drug exposure has a limited duration 28 (+/- 5) days and at lower dose (600mg/day) than therapeutical accepted (800mg/day).</description>
          </group>
        </group_list>
        <measure>
          <title>Protein Expression of Biomarkers Related to PARP-inhibition</title>
          <description>We assessed the change from baseline in the H-score of several biomarkers targeted by olaparib-based therapy on endometrial tumor tissues after 28 (+/- 5) days of treatment. In detail, expression of protein involved in the DNA repair (PARP1, ɣH2AX), angiogenesis (VEG, HIF-1α, PTEN), apoptosis (p65, p50, p53), glucose metabolism (GLUT1), proliferation (PH3), and regulation of gene transcription (ARID1A) were evaluated by an H-score according to the following formula:
H-score= 1x(%light staining) + 2x(%moderate staining) + 3x(%strong staining).
The final score ranges from 0 to 300, where 0 indicates absence of staining and 300 the maximum staining.</description>
          <population>The analysis was performed in the complete population of analysis (N = 36) and in the population of biomarkers (N = 31).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PARP1 pre-treatment - post-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" spread="46.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>y-H2AX pre-treatment - post-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.21" spread="67.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF pre-treatment - post-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.4" spread="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HIF-1α pre-treatment - post-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9" spread="74.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTEN pre-treatment - post-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P65 pre-treatment - post-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P50 pre-treatment - post-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P53 pre-treatment - post-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GLUT1 active pre-treatment - post-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.8" spread="66.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PHH3 pre-treatment - post-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARID1A pre-treatment - post-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>After having analyzed the H-score for each of several biomarkers, we calculated the change from baseline subtracting post-treatment H-score from baseline H-score. Data were expressed as mean value and relative standard deviation.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The differences in the change from baseline of different biomarkers were evaluated by the P-valor Wilcoxon method, a non-parametric statistical hypothesis test.</non_inferiority_desc>
            <p_value>0.03</p_value>
            <p_value_desc>In order to adjust the multiple comparisons made, Benjamini-Hochberg's false discovery rate (FDR) 10% method was used.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Levels of Olaparib</title>
        <description>Plasma concentration of olaparib administered at dosis of 300mg twice in a day (600mg/day). Values of plasma level of olaparib on days 7,14,21 and 28 were collected at time when maximum of drug concentration is reached. Data are reported as µg/mL.</description>
        <time_frame>Days 7,14,21 and 28</time_frame>
        <population>The analysis was performed in the overall population of analysis (N = 36)</population>
        <group_list>
          <group group_id="O1">
            <title>Olaparib</title>
            <description>Drug exposure has a limited duration 28 (+/- 5) days.
Olaparib: Drug exposure has a limited duration 28 (+/- 5) days and at lower dose (600mg/day) than therapeutical accepted (800mg/day).</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Levels of Olaparib</title>
          <description>Plasma concentration of olaparib administered at dosis of 300mg twice in a day (600mg/day). Values of plasma level of olaparib on days 7,14,21 and 28 were collected at time when maximum of drug concentration is reached. Data are reported as µg/mL.</description>
          <population>The analysis was performed in the overall population of analysis (N = 36)</population>
          <units>µg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 07</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.55" spread="2.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.61" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.49" spread="2.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="3.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Olaparib-Associated Toxicities</title>
        <description>To assess the tolerability for all treated patients (N=36) according to NCI-CTCAE v.4.03.</description>
        <time_frame>Up to 28 days (+/- 5)</time_frame>
        <population>The analysis was performed in the complete population of analysis (N = 36) and took in account patients who discontinued study for drug-associated toxicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Olaparib</title>
            <description>Drug exposure has a limited duration 28 (+/- 5) days.
Olaparib: Drug exposure has a limited duration 28 (+/- 5) days and at lower dose (600mg/day) than therapeutical accepted (800mg/day).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Olaparib-Associated Toxicities</title>
          <description>To assess the tolerability for all treated patients (N=36) according to NCI-CTCAE v.4.03.</description>
          <population>The analysis was performed in the complete population of analysis (N = 36) and took in account patients who discontinued study for drug-associated toxicity.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the first day of treatment initiation until to 28 days (+/- 7 days) after the last day of study treatment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Olaparib</title>
          <description>Drug exposure has a limited duration 28 (+/- 5) days.
Olaparib: Drug exposure has a limited duration 28 (+/- 5) days and at lower dose (600mg/day) than therapeutical accepted (800mg/day).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Post-surgical wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Operations</name_or_title>
      <organization>Medica Scientia Innovation Research (MedSIR)</organization>
      <phone>0034 932 214 135</phone>
      <email>alicia.garcia@medsir.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

